...
首页> 外文期刊>Process Biochemistry >Mechanism-based antidiabetic activity of Fructo- and isomalto-oligosaccharides: Validation by in vivo, in silico and in vitro interaction potential
【24h】

Mechanism-based antidiabetic activity of Fructo- and isomalto-oligosaccharides: Validation by in vivo, in silico and in vitro interaction potential

机译:果糖和异麦芽低聚糖的基于机制的抗糖尿病活性:通过体内,计算机和体外相互作用潜力进行验证

获取原文
获取原文并翻译 | 示例

摘要

This study evaluates the relative beneficial effects of 10% dietary intake of fructooligosaccharides (FOSs) and isomaltooligosaccharides (IMOs) and combination of FOS +IMO in poloxamer-407 (PX-407) induced type 2 diabetic Wistar rats. FOSs was produced from Aspergillus oryzae (MTCC5154) while IMOs and standards of 1-kestose, 1-nystose, 1-fructofuranosyl nystose and panose were procured. In silico docking studies were performed by GLIDE program for each of the FOSs and IMOs for PPAR-γ activation and DPP-Ⅳ inhibition. Diabetic rats treated with FOS + IMO showed relatively more amelioration of glycemic and lipid dysmetabolism, remarkable reduction in oxidative markers, increased GLP-1 content as well as Bifidobacteria/Lactobacilli population in caecum than lone FOSs/IMOs treatment. Out of nine oligosac-charides docked from FOS and IMO; panose, nystose and kestose showed highest ranking binding mode with DPP-IV and PPAR-γ and were selected for in vitro study either alone or in combinations. On its own nystose showed potent DPP-IV inhibitory activity with an IC50 of 146.8 μM while panose at 20.2 μM concentrations showed 50% binding ability to PPAR-γ-LBD. Combinations of oligosaccharides tested namely Nys + Pan, Nys + Kes and Pan + Kes demonstrated significant (p < 0.001) effect on PPAR-γ/DPP-Ⅳ bioassay. The results provide pharmacological evidence of FOSs and IMOs as antihyperglycemic mediated by their interaction with multiple targets operating in diabetes particularly nystose and pannose.
机译:这项研究评估了果糖低聚糖(FOSs)和异麦芽低聚糖(IMOs)的10%日粮摄入量以及FOS + IMO组合对poloxamer-407(PX-407)诱导的2型糖尿病Wistar大鼠的相对有益作用。从米曲霉(MTCC5154)生产FOS,同时采购IMO和1-Kest​​ose,1-nystose,1-fructofuranosyl nystose和panose的标准品。通过GLIDE程序对POS-γ激活和DPP-Ⅳ抑制的FOS和IMO进行了计算机对接研究。与单独的FOSs / IMOs治疗相比,用FOS + IMO治疗的糖尿病大鼠在盲肠中的血糖和脂质代谢异常改善程度更大,氧化标记物显着减少,GLP-1含量增加,双歧杆菌/乳酸杆菌数量增加。从FOS和IMO对接的9个寡糖中。 Panose,Nystose和Kestose与DPP-IV和PPAR-γ表现出最高等级的结合模式,并且被单独或组合选择用于体外研究。褐藻糖单独显示出强效的DPP-IV抑制活性,IC50为146.8μM,而浓度为20.2μM的聚乳糖则显示出与PPAR-γ-LBD的50%结合能力。测试的低聚糖组合Nys + Pan,Nys + Kes和Pan + Kes对PPAR-γ/DPP-Ⅳ生物测定具有显着(p <0.001)影响。该结果提供了FOS和IMO作为降糖药的药理学证据,它们是通过与糖尿病患者中的多个靶点(尤其是犬菊糖和潘尼糖)相互作用而介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号